Antibiotice SA
BBVB:ATB2.00
RON
0.00
(0.00%)
Antibiotice SA
BVB:ATB
(Bucharest Stock Exchange)
Recent
price
2.00
P/E
ratio
178.68
div
yld
0.89%
ROIC.AI
Capital Structure
RON
•
in mil. unless spec.Working Capital
RON
•
in mil. unless spec.Growth Rates
RON
•
in mil. unless spec.Quarterly Revenue
RON
•
in mil. unless spec.Quarterly Earnings Per Share
RON
•
in mil. unless spec.Quarterly Dividends Per Share
RON
•
in mil. unless spec.- Similar Companies
- Business
- Antibiotice SA is a Romania-based pharmaceutical manufacturing company primarily engaged in the development, production, and commercialization of generic prescription drugs, active pharmaceutical ingredients, over-the-counter medicines, and sterile hospital-use pharmaceuticals. Founded in 1955 and headquartered in Iași, Romania, the company serves institutional healthcare systems, wholesale pharmaceutical distributors, and retail pharmacy networks across domestic and international markets. The company's core product and service offerings comprise systemic anti-infective medications, including penicillin derivatives, cephalosporins, and carbapenems supplied in sterile injectable powders, capsules, and tablets; active pharmaceutical ingredients (APIs), led by its position as a major global producer of Nystatin API synthesized via microbiological fermentation; topical semi-solid formulations, including therapeutic ointments, creams, and dermatological gels marketed under brand lines such as Cutaden, Saliform, and Clotrimazol; rectal and vaginal solid dosage forms, consisting of suppositories and pessaries; oral solid dosage therapies addressing cardiovascular, central nervous system, gastrointestinal, musculoskeletal, and metabolic indications; consumer healthcare products, food supplements, and vitamins marketed under the Nutriensa brand portfolio; and third-party contract manufacturing, chemical and microbiological analytical testing, formulation research, and regulatory dossier licensing services. Antibiotice SA distributes its products across Romania and exports to more than 60 countries across North America, Europe, Latin America, Asia, and the Middle East, supported by international commercial representative offices in territories such as Vietnam, the Republic of Moldova, and Serbia. In recent developments, the company is executing its multi-year "The Future Together 2030" strategic investment program aimed at doubling business turnover, modernizing manufacturing capacity, and expanding international market penetration. Key recent initiatives include the operationalization of a newly built, automated production plant in Iași dedicated to topical semi-solids and suppositories to serve regulated export markets; the installation and commissioning of on-site industrial photovoltaic energy parks to optimize production sustainability and operational efficiency; the expansion of international public procurement tender awards for critical sterile injectable antibiotics in European and United States hospital networks; the strategic portfolio diversification into oncology, cardiology, and specialty therapeutic areas through in-licensing and co-development partnerships; and intensified capital investments in advanced formulation and analytical research laboratories to accelerate new generic product development and global regulatory approvals.